United States

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

28 Apr 2017
Change (% chg)

$-0.09 (-2.45%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins
Thursday, 20 Apr 2017 08:50am EDT 

April 20 (Reuters) - Agenus Inc :Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins.Agenus Inc - Preliminary safety and efficacy data are expected to be available within next 9-12 months from AGEN2034 study.  Full Article

Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax
Wednesday, 5 Apr 2017 08:50am EDT 

Agenus Inc : Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax .Agenus Inc - preclinical data presented at AACR 2017 annual meeting show ASV to be active and synergistic with checkpoint blockade.  Full Article

Agenus says plans to close Basel site, combine key functions to Cambridge, UK and Lexington, MA facilities
Thursday, 30 Mar 2017 06:45am EDT 

Agenus Inc : Agenus restructures business to sharpen focus on clinical development of cancer therapies . Agenus - plans to close Basel site, consolidate key functions to Cambridge, UK and Lexington, MA facilities, and phase out approximately 50 positions . Agenus Inc - Robert Stein, M.D., Ph.D., president of research and development, will retire to become a senior research and development advisor exclusive to Agenus .Says as part of restructuring, approximately 50 positions are planned to be phased out within next six months.  Full Article

QVT Financial reports 5.08 pct passive stake in Agenus
Friday, 3 Feb 2017 05:03pm EST 

Agenus Inc :QVT Financial Lp reports a 5.08 percent passive stake in Agenus Inc as of January 24, 2017 - sec filing.  Full Article

Agenus files for offering of up to 157,513 shares by selling stockholder
Friday, 20 Jan 2017 04:21pm EST 

Agenus Inc :Files for offering of up to 157,513 shares of co's common stock by the selling stockholder - SEC filing.  Full Article

Agenus Q2 loss per share $0.33
Thursday, 28 Jul 2016 08:50am EDT 

Agenus Inc : Qtrly revenue $6.6 million versus $6.4 million . Agenus reports second quarter 2016 financial results and operational progress . Q2 loss per share $0.33 . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S .Q2 revenue view $5.1 million -- Thomson Reuters I/B/E/S.  Full Article

Agenus' chief financial officer, C.Evan Ballantyne to resign
Tuesday, 19 Jul 2016 08:51am EDT 

Agenus Inc : On july 14, 2016, C. Evan Ballantyne, chief financial officer informed agenus of his intention to resign - sec filing .Christin Klaskin, Agenus' VP, finance and principal accounting officer, will retain her roles, assume role of principal financial officer.  Full Article

Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody
Wednesday, 22 Jun 2016 08:50am EDT 

Agenus Inc : Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months .Agenus announces commencement of phase 1/2 clinical trial of anti-GITR checkpoint antibody INCAGN1876 in patients with solid tumors.  Full Article

Agenus Inc acquires PhosImmune
Wednesday, 23 Dec 2015 08:00am EST 

Agenus Inc:Acquired privately-held PhosImmune Inc., a company that has discovered an entirely new portfolio of cancer neoantigens.The acquisition provides Agenus the ability to accelerate the development of new cancer vaccines and other single agent immuno-oncology approaches, as well as combination therapies.Under the terms of the agreement, Agenus paid PhosImmune's equity holders an upfront payment of $2.5 million in cash and $7.4 million in shares of Agenus common stock at closing.Additional payments of up to $35 million in cash and/or stock at Agenus' election are payable upon the achievement of certain.  Full Article

Agenus to acquire antibody manufacturing capability and capabilities from XOMA
Thursday, 5 Nov 2015 04:00pm EST 

Agenus Inc:To acquire biologics manufacturing facility and capabilities from XOMA.Acquires rights to Selexis cell line development technology.Purchases an exclusive license to a Phage Display library from Iontas.Under the terms of the agreement with XOMA, Agenus will pay at closing $5.0 million in cash and up to $1.0 million in common stock.  Full Article

More From Around the Web